Sai Life Sciences (NSE:SAILIFE) Piotroski F-Score: 6 (As of Jun. 28, 2026) — 33% Below Median


NSE:SAILIFE Sai Life Sciences Ltd NSE:SAILIFE
18 GF Score
Price ₹1,221.30
! 5 Warning Signs
View Full Analysis

What is Sai Life Sciences Piotroski F-Score?

Sai Life Sciences NSE:SAILIFE +1.35% 18 Piotroski F-Score is 6 as of Jun. 28, 2026, which is 33% below its 10-year median of 9.00. GuruFocus rates NSE:SAILIFE with a GF Score™ of 18/100. The stock has 5 warning signs investors should review. Among 210 Medical Diagnostics & Research companies, Sai Life Sciences ranks better than 79.52% on this metric.

The zones of discrimination were as such:

Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3

Sai Life Sciences has an F-score of 6 indicating the company's financial situation is typical for a stable company.

The historical rank and industry rank for Sai Life Sciences's Piotroski F-Score or its related term are showing as below:

NSE:SAILIFE' s Piotroski F-Score Range Over the Past 10 Years
Min: 6   Med: 9   Max: 9
Current: 6

During the past 5 years, the highest Piotroski F-Score of Sai Life Sciences was 9. The lowest was 6. And the median was 9.

Sai Life Sciences  (NSE:SAILIFE) Piotroski F-Score Explanation

The developer of the system is Joseph D. Piotroski is relatively unknown accounting professor who shuns publicity and rarely gives interviews.

He graduated from the University of Illinois with a B.S. in accounting in 1989, received an M.B.A. from Indiana University in 1994. Five years later, in 1999, after earning a Ph.D. in accounting from the University of Michigan, he became an associate professor of accounting at the University of Chicago.

In 2000, he wrote a research paper called "Value Investing: The Use of Historical Financial Statement Information to Separate Winners from Losers" (pdf).

He wanted to see if he can develop a system (using a simple nine-point scoring system) that can increase the returns of a strategy of investing in low price to book (referred to in the paper as high book to market) value companies.

What he found was something that exceeded his most optimistic expectations.

Buying only those companies that scored highest (8 or 9) on his nine-point scale, or F-Score as he called it, over the 20 year period from 1976 to 1996 led to an average out-performance over the market of 13.4%.

Even more impressive were the results of a strategy of investing in the highest F-Score companies (8 or 9) and shorting companies with the lowest F-Score (0 or 1).

Over the same period from 1976 to 1996 (20 years) this strategy led to an average yearly return of 23%, substantially outperforming the average S&P 500 index return of 15.83% over the same period.


Sai Life Sciences Piotroski F-Score Related Terms


Sai Life Sciences Piotroski F-Score Historical Data

* Premium members only.

The historical data trend for Sai Life Sciences's Piotroski F-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Sai Life Sciences Piotroski F-Score Chart

Sai Life Sciences Annual Data
Trend Mar22 Mar23 Mar24 Mar25 Mar26
Piotroski F-Score
N/A N/A 9.00 9.00 6.00

Sai Life Sciences Quarterly Data
Mar22 Mar23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Piotroski F-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only 9.00 0.00 0.00 0.00 6.00

NSE:SAILIFE vs TMO, DHR, IDXX: Piotroski F-Score Comparison

For the Diagnostics & Research subindustry, Sai Life Sciences's Piotroski F-Score, along with its competitors' market caps and Piotroski F-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Sai Life Sciences Piotroski F-Score vs Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Sai Life Sciences's Piotroski F-Score distribution charts can be found below:

* The bar in red indicates where Sai Life Sciences's Piotroski F-Score falls into.


NSE:SAILIFE
18GF Score
Sai Life Sciences Ltd NSE:SAILIFE
Piotroski F-Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

How is the Piotroski F-Score calculated?

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

This Year (Mar26) TTM:Last Year (Mar25) TTM:
Net Income was ₹3,489 Mil.
Cash Flow from Operations was ₹5,091 Mil.
Revenue was ₹21,925 Mil.
Gross Profit was ₹9,385 Mil.
Average Total Assets from the begining of this year (Mar25)
to the end of this year (Mar26) was (31599.75 + 36261.4) / 2 = ₹33930.575 Mil.
Total Assets at the begining of this year (Mar25) was ₹31,600 Mil.
Long-Term Debt & Capital Lease Obligation was ₹1,481 Mil.
Total Current Assets was ₹14,105 Mil.
Total Current Liabilities was ₹8,337 Mil.
Net Income was ₹1,701 Mil.

Revenue was ₹16,946 Mil.
Gross Profit was ₹6,797 Mil.
Average Total Assets from the begining of last year (Mar24)
to the end of last year (Mar25) was (22751.36 + 31599.75) / 2 = ₹27175.555 Mil.
Total Assets at the begining of last year (Mar24) was ₹22,751 Mil.
Long-Term Debt & Capital Lease Obligation was ₹1,647 Mil.
Total Current Assets was ₹15,045 Mil.
Total Current Liabilities was ₹7,325 Mil.

*Note: If the latest quarterly/semi-annual/annual total assets data is 0, then we will use previous quarterly/semi-annual/annual data for all the items in the balance sheet.

Profitability

Question 1. Return on Assets (ROA)

Net income before extraordinary items for the year divided by Total Assets at the beginning of the year.

Score 1 if positive, 0 if negative.

Sai Life Sciences's current Net Income (TTM) was 3,489. ==> Positive ==> Score 1.

Question 2. Cash Flow Return on Assets (CFROA)

Net cash flow from operating activities (operating cash flow) divided by Total Assets at the beginning of the year.

Score 1 if positive, 0 if negative.

Sai Life Sciences's current Cash Flow from Operations (TTM) was 5,091. ==> Positive ==> Score 1.

Question 3. Change in Return on Assets

Compare this year's return on assets (1) to last year's return on assets.

Score 1 if it's higher, 0 if it's lower.

ROA (This Year)=Net Income/Total Assets (Mar25)
=3489.1/31599.75
=0.11041543

ROA (Last Year)=Net Income/Total Assets (Mar24)
=1701.32/22751.36
=0.07477883

Sai Life Sciences's return on assets of this year was 0.11041543. Sai Life Sciences's return on assets of last year was 0.07477883. ==> This year is higher. ==> Score 1.

Question 4. Quality of Earnings (Accrual)

Compare Cash flow return on assets (2) to return on assets (1)

Score 1 if CFROA > ROA, 0 if CFROA <= ROA.

Sai Life Sciences's current Net Income (TTM) was 3,489. Sai Life Sciences's current Cash Flow from Operations (TTM) was 5,091. ==> 5,091 > 3,489 ==> CFROA > ROA ==> Score 1.

Funding

Question 5. Change in Gearing or Leverage

Compare this year's gearing (long-term debt divided by average total assets) to last year's gearing.

Score 0 if this year's gearing is higher, 1 otherwise.

Gearing (This Year: Mar26)=Long-Term Debt & Capital Lease Obligation/Average Total Assets from Mar25 to Mar26
=1481.24/33930.575
=0.04365502

Gearing (Last Year: Mar25)=Long-Term Debt & Capital Lease Obligation/Average Total Assets from Mar24 to Mar25
=1646.87/27175.555
=0.06060115

Sai Life Sciences's gearing of this year was 0.04365502. Sai Life Sciences's gearing of last year was 0.06060115. ==> This year is lower or equal to last year. ==> Score 1.

Question 6. Change in Working Capital (Liquidity)

Compare this year's current ratio (current assets divided by current liabilities) to last year's current ratio.

Score 1 if this year's current ratio is higher, 0 if it's lower

Current Ratio (This Year: Mar26)=Total Current Assets/Total Current Liabilities
=14105.3/8336.78
=1.69193622

Current Ratio (Last Year: Mar25)=Total Current Assets/Total Current Liabilities
=15045.11/7324.9
=2.05396797

Sai Life Sciences's current ratio of this year was 1.69193622. Sai Life Sciences's current ratio of last year was 2.05396797. ==> Last year's current ratio is higher ==> Score 0.

Question 7. Change in Shares in Issue

Compare the number of shares in issue this year, to the number in issue last year.

Score 0 if there is larger number of shares in issue this year, 1 otherwise.

Sai Life Sciences's number of shares in issue this year was 212.362. Sai Life Sciences's number of shares in issue last year was 197.598. ==> There is larger number of shares in issue this year. ==> Score 0.

Efficiency

Question 8. Change in Gross Margin

Compare this year's gross margin (Gross Profit divided by sales) to last year's.

Score 1 if this year's gross margin is higher, 0 if it's lower.

Gross Margin (This Year: TTM)=Gross Profit/Revenue
=9385.45/21924.92
=0.42807226

Gross Margin (Last Year: TTM)=Gross Profit/Revenue
=6796.88/16945.7
=0.40109762

Sai Life Sciences's gross margin of this year was 0.42807226. Sai Life Sciences's gross margin of last year was 0.40109762. ==> This year's gross margin is higher. ==> Score 1.

Question 9. Change in asset turnover

Compare this year's asset turnover (total sales for the year divided by total assets at the beginning of the year) to last year's asset turnover ratio.

Score 1 if this year's asset turnover ratio is higher, 0 if it's lower

Asset Turnover (This Year)=Revenue/Total Assets at the Beginning of This Year (Mar25)
=21924.92/31599.75
=0.69383207

Asset Turnover (Last Year)=Revenue/Total Assets at the Beginning of Last Year (Mar24)
=16945.7/22751.36
=0.74482141

Sai Life Sciences's asset turnover of this year was 0.69383207. Sai Life Sciences's asset turnover of last year was 0.74482141. ==> Last year's asset turnover is higher ==> Score 0.

Evaluation

Piotroski F-Score= Que. 1+ Que. 2+ Que. 3+Que. 4+Que. 5+Que. 6+Que. 7+Que. 8+Que. 9
=1+1+1+1+1+0+0+1+0
=6

Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3

Sai Life Sciences has an F-score of 6 indicating the company's financial situation is typical for a stable company.

Frequently Asked Questions Learn more about Piotroski F-Score →
What does a Piotroski F-Score of 6 mean?
Sai Life Sciences (NSE:SAILIFE) has a Piotroski F-Score of 6 as of Jun. 28, 2026. The Piotroski F-score grades a company's business operating strength from 0-9. View historical data on Sai Life Sciences and its competitors. This is 33% below median its historical median of 9.00. Over the past decade, Sai Life Sciences' Piotroski F-Score has ranged from 6.00 to 9.00. According to the industry distribution chart, Sai Life Sciences ranks #43 out of 210 companies in the Medical Diagnostics & Research industry, placing it in the top 20.5%.
Is Sai Life Sciences' Piotroski F-Score too high?
Sai Life Sciences' current Piotroski F-Score of 6 is 33% below median its 10-year median of 9.00. Over the past 10 years, this metric has ranged from a low of 6.00 to a high of 9.00. The Medical Diagnostics & Research industry median Piotroski F-Score is 5.00. Sai Life Sciences' value of 6 is 20% above this industry median. Based on the distribution chart, Sai Life Sciences ranks #43 out of 210 companies in the Medical Diagnostics & Research industry, which is in the top quartile — a strong position relative to peers. Overall, Sai Life Sciences has a GF Score™ of 18/100, reflecting its overall financial health beyond just this single metric.
How does Sai Life Sciences' Piotroski F-Score compare to TMO and DHR?
According to the Medical Diagnostics & Research industry distribution chart, Sai Life Sciences ranks #43 out of 210 companies for Piotroski F-Score. This places Sai Life Sciences in the top 21% of its industry — outperforming the majority of peers. The industry median Piotroski F-Score is 5.00. Sai Life Sciences' value of 6 is 20% above this benchmark. Historically, Sai Life Sciences' own Piotroski F-Score has ranged from 6.00 to 9.00 over the past decade. While the company's 10-year median is 9.00 vs. the industry median of 5.00, Sai Life Sciences has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Piotroski F-Score for a Medical Diagnostics & Research company?
The median Piotroski F-Score among Medical Diagnostics & Research companies is 5.00, based on 210 companies in the industry. Companies in the top quartile (top 25%) have a Piotroski F-Score significantly above this median, while those in the bottom quartile fall well below. However, Piotroski F-Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Sai Life Sciences's current Piotroski F-Score of 6 is 20% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Piotroski F-Score mean?
A high Piotroski F-Score can signal that a stock is expensive relative to its fundamentals. The Piotroski F-score grades a company's business operating strength from 0-9. View historical data on Sai Life Sciences and its competitors. For the Medical Diagnostics & Research industry, the median Piotroski F-Score is 5.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Sai Life Sciences's current Piotroski F-Score is 6, which is 33% below median its own 10-year median of 9.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Sai Life Sciences stock overvalued right now?
Sai Life Sciences (NSE:SAILIFE) has a current Piotroski F-Score of 6. The current Piotroski F-Score is 6, which is 33% below median its 10-year median of 9.00 and 20% above the Medical Diagnostics & Research industry median of 5.00. Sai Life Sciences' overall GF Score™ is 18/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Piotroski F-Score calculated?
Piotroski F-Score is calculated from a company's financial statements. For Sai Life Sciences (NSE:SAILIFE), the current Piotroski F-Score is 6 as of Jun. 28, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Sai Life Sciences Business Description

Other Exchanges 544306:India
Address Gachibowli Miyapur Road, L4- 01 & 02, SLN Terminus Survey, Survey no. 133, Gachibowli, Hyderabad, TG, IND, 500032
Sai Life Sciences Ltd is an innovator-focused, contract research, development, and manufacturing organization. It provides end-to-end services across the drug discovery, development, and manufacturing value chain, for small molecule new chemical entities (NCE), to pharmaceutical innovator companies and biotechnology firms. It possesses both; discovery/contract research (CRO) and chemistry, manufacturing, and control (CMC)/contract development and manufacturing organization (CDMO) capabilities. The company has only one reportable segment: contract research, development, and manufacturing. Geographically it operates in India as well as Outside India.
18GF Score

Get the complete analysis for NSE:SAILIFE

Piotroski F-Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₹1,221.30
Price